The Australian CRO (contract research organisation) says its new offering – geared towards Phase I & II trials – is made up of an international, multi-disciplinary network of preclinical and regulatory consultants.
The company will then tailor the “ideal team” to suit each project, who will work with clients from product profiling right up to support finding investors.
Russell Neal, chief operating officer of CNS, told Outsourcing-Pharma that the level of service they can provide is unique for a company in Australia or New Zealand.
He added: “Our service works because it is a sum of the parts.
“For CNS’s clients, who are smaller with fewer internal resources, it is critical for them to establish trusted consultant relationships and gain applicable and strategic international regulatory advice for their programs.
“We can relate to target plans small company to small company.”
Services for all
With the appointment of gene therapy and genetically modified organisms (GMOs) expert Mark Reid, who will become the leader of the new service offering, Outsourcing-Pharma put the question to Neal whether the company would specialize in this field.
“No - we haven’t specialised, nor will we,” he replied.
“We provide services to all therapeutic areas and technologies. However, Mark does bring rare insight and experience to gene therapy and biological in general. “